




ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger

Judith U. Kim  
Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Eldora L. Ellison  
Thomas C. Fiala  
Donald R. Banowitz  
Peter A. Jackman  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Brian J. Del Buono  
Virgil Lee Beaston  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Rae Lynn P. Guest

Daniel A. Klein  
Jason D. Eisenberg  
Michael D. Specht  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longsworth  
Lori A. Gordon  
Nicole D. Dretar  
Ted J. Ebersole  
Laura A. Vogel  
Bryan S. Wade  
Aaron L. Schwartz  
Shannon A. Carroll\*

Wesley W. Jones\*  
Matthew E. Kelley\*  
Michelle K. Holoubek\*  
Marsha A. Rose\*  
**Registered Patent Agents**  
Karen R. Markowitz  
Nancy J. Leith  
Matthew J. Dowd  
Katrina Yujia Pei Quach  
Bryan L. Skeeton  
Robert A. Schwartzman  
Teresa A. Colella  
Victoria S. Rutherford  
Simon J. Elliott  
Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse

Christopher J. Walsh  
Liliana Di Nola-Baron  
Peter A. Socarras  
Jeffrey Mills  
Danielle L. Letting  
**Of Counsel**  
Kenneth C. Bass III  
Marvin C. Guthrie  
  
\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

January 11, 2006

WRITER'S DIRECT NUMBER:  
(202) 772-8846

INTERNET ADDRESS:  
PCALVO@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Art Unit 1644

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application  
Application No. 09/583,200; Filed: May 30, 2000  
For: **HLA Class I A2 Tumor Associated Antigen  
Peptides and Vaccine Compositions**  
Inventors: **FIKES et al.**  
Our Ref: 2060.0150002/EKS/PAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Submission of Substitute Sequence Listing;
2. 24 pages of Substitute Sequence Listing;
3. Computer readable copy of the Substitute Sequence Listing; and
4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE KESSLER, GOLDSTEIN & FOX P.L.L.C.

Paul A. Calvo  
Agent for Applicants  
Registration No. 57,913

EKS/PAC/dbj

Enclosures

Sterne, Kessler, Goldstein & Fox P.L.L.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : [www.skgf.com](http://www.skgf.com)

483490\_1.DOC



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
Fikes *et al.*  
Appl. No.: 09/583,200  
Filed: May 30, 2000  
For: **HLA Class I A2 Tumor  
Associated Antigen Peptides  
and Vaccine Compositions**

Confirmation No.: 1443  
Art Unit: 1644  
Examiner: Schwadron, R.B.  
Atty. Docket: 2060.0150002/EKS/PAC

**Amendment and Submission of Substitute Sequence Listing**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In the above identified matter, and in advance of prosecution, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

**Amendments to the Specification** begin on Page 2.

**Amendments to the Sequence Listing** begin on Page 4 and include an attached Sequence Listing.

**Remarks** begin on Page 5.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. §1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.